Task force softens stance on bladder cancer screening
In an update to its 2004 recommendation, the U.S. Preventive Services Task Force has concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults.
In an update to its 2004 recommendation, the U.S. Preventive Services Task Force has concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults.
Previously, the USPSTF concluded that the harms outweighed the benefits of screening for bladder cancer. The update focused on the benefits and harms of screening among people without symptoms, the accuracy of screening tests done in primary care settings, and the benefits and harms of treatment.
"The updated evidence review did not find any new high-quality evidence to adequately determine the balance of benefits and harms of screening for bladder cancer," the USPSTF said in a statement. "However, bladder cancer is a common cancer and can cause considerable health problems including death. Therefore, the Task Force determined that the evidence was insufficient to provide a recommendation for or against bladder cancer screening."
The USPSTF emphasized the need for additional research in this area.
The updated recommendation was published in the Annals of Internal Medicine (2011; 155:246-51).
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
